



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/812,318	03/29/2004		Joost Dick de Bruijn	04148-00100	1826
22910	7590	08/18/2005		EXAMINER	
		OFF, LTD.	FORD, ALLISON M		
28 STATE S 28th FLOOR			ART UNIT	PAPER NUMBER	
BOSTON, 1	MA 0210	9-9601	1651		
				DATE MAILED: 08/18/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/812,318	DE BRUIJN ET AL.					
Office Action Summary	Examiner	Art Unit					
•	Allison M. Ford	1651					
The MAILING DATE of this communication app							
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on	Responsive to communication(s) filed on						
,—	This action is FINAL . 2b)⊠ This action is non-final.						
• •	· · · · · · · · · · · · · · · · · · ·						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-19</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to.							
8) Claim(s) 1-19 are subject to restriction and/or e	election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
······································							
AMarkov v. (C.)							
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date.							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:	atent Application (PTO-152)					
S. Patent and Trademark Office							

Application/Control Number: 10/812,318 Page 2

Art Unit: 1651

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-14 and 17-19, drawn to an injectable bone filler composition and methods

related thereto, classified in class 623, subclass 16.11.

II. Claims 15-16, drawn to a syringe, classified in class D24, subclass 130.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the syringe product of invention II can be used for many applications besides the injection of the bone filler composition of invention I. For example, a syringe is commonly used to withdraw blood fluids for testing purposes; this is a materially different process than the injection of bone filler composition, thus the product of invention II can be used for materially different processes than that of invention I.

Therefore, a search and examination of all inventions in one patent application would result in an undue burden. These inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, different classifications, and a search for one group does not require a search for another group, restriction for examination purposes as indicated is proper.

Upon the election of invention I, the following elections of species are required:

Art Unit: 1651

This application contains claims directed to the following patentably distinct species of the claimed invention:

- 1. Type of calcium salt particles: (a) calcium phosphates, (b) monetite, (c) brushite, (d) CaHPO₄, (e) calcium pyrophosphate, (f) calcium carbonate, (g) combinations of (a)-(f), (h) hydroxyapatite, (i) beta-calcium phosphate, (j) combinations of (h)-(i)
- 2. Type of binder: (k) alginates (including sodium alginate), (l) dextrans (including dextran) (m) cellulose & cellulose derivatives (including sodium carboxymethyl cellulose), (n) plasma, (o) biogenic binders (including fibrin glue), (p) hyaluronic acid, (q) combinations of (k)-(p), and (q) trans glutaminase

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from each group for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of

Application/Control Number: 10/812,318 Page 4

Art Unit: 1651

the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under

35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of

the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named

inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of

inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37

CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Allison M. Ford whose telephone number is 571-272-2936. The examiner can normally be

reached on 7:30-5 M-Th, alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where

this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained

from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-

direct uspto gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Allison M Ford Examiner Art Unit 1651

> LEON & LANKFORD, JR. PRIMARY EXAMINER